|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Ensemble Therapeutics Corporation Presents Oral Efficacy of First-in-Class Small Molecule Targeting IL-17 for Inflammation in Preclinical Studies
11/12/2012 9:45:46 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics, a biotechnology company developing EnsemblinsTM, a novel class of small molecule therapeutics with the power of biologics, announced today positive preclinical oral efficacy data with its first-in-class small molecule Interleukin-17 (IL-17) antagonists. A presentation at the American College of Rheumatology (ACR) 2012 Annual Meeting, taking place November 9-14, 2012 in Washington, DC, revealed that the company’s Ensemblins have strong oral activity as antagonists of IL-17, a pro-inflammatory cytokine implicated in multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn’s disease and inflammatory bowel disease.
|
|
|
|
|
|
|
|
|
|
|